You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Detection and Staging of Liver Fibrosis by Precise MRI (pMRI)
SBC: INLIGHTA BIOSCIENCES L.L.C. Topic: NIAAAAbstract Chronic liver injury due to alcohol, metabolic dysfunction, viral hepatitis, or autoimmune disease results in liver inflammation and fibrosis. Liver fibrosis will progress to cirrhosis which is estimated to affect 1–2% of the world’s population. The major clinical consequences of cirrhosis are liver failure and hepatocellular carcinoma (HCC), both of which increase the risk of death. ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a protein drug for pancreatic cancer treatment
SBC: ProDa BioTech L.L.C. Topic: NCIAbstract Pancreatic cancers are devastating diseases with five year survival rate less thanCurrentlythere is no effective treatment for advanced diseaseOne major barrier to efficacy of anti tumor therapeutics is the dense desmoplastic stromal responseEvidence suggests that cancer associated pancreatic stellate cellsCAPaSCproduce the stromal collagenThe ECM laid down by CAPaSC is considered to be o ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer: Nanoscale Bio-Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygenOcarrier to substitute for banked blood in settings wherestored blood is unavailablepre hospital care transportaustere environmentsundeveloped countriesorundesirabletransfusion risk exceeds benefitTo address this needwe developedErythroMerEMa first inclass nano cyte blood substituteEM is a deformablecross linked polymeric nanoparticle that inco ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Expansion of Immuno-CometChip Platform
SBC: AMELIA TECHNOLOGIES LLC Topic: NIEHSProject SummaryThe objective of this supplementation request is to further our recent advances in the development of thewell Immuno CometChip assay results and build a prototypewell preformer giving the assay more utility and increasing commercial viability
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
SBC: CAPELLA IMAGING, LLC Topic: NHLBIDespite the myriad major advances in cardiologythe prognosis for patients with severemedically refractive heart failureHFis exceedingly poorApproximatelydeaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizationsAt leastof these deaths were directly related to severe heart fai ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
OC-Go: Facilitating fidelity and dissemination of evidence based treatment for childhood OCD via an interactive crowd-sourced patient-provider tool
SBC: VIRTUALLY BETTER INC Topic: 104The long term objective of this project is to leverage mobile technologies and crowdsourcing to create a new paradigm of evidence based treatment delivery and disseminationas current methods are often insufficientThe project seeks to refine and assess OC Goa HIPAA compliant web based clinician portal and patient side mobile application designed to increase patient adherence to evidence based treat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
An unique patient population for clinical trials against noise-induced hearing loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDAbstractNoise is the number one occupational and environmental hazardand noiseinduced hearing lossNIHLis one common form of sensorineural hearing deficitonly second to age related hearing lossCurrently no drug preventing NIHL is approved by the United States Food and Drug AdministrationFDAOne major challenge for the introduction of such interventions is the need to identify appropriate human popul ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse
SBC: NEUROP, INC. Topic: NIDAAbstract The current status of opiate abuse in the US has been characterized as arapidly evolving publichealth crisisrequiring the need for new treatments to address the problemPersistent relapse toaddictive drug use is a significant challenge to addiction therapyMedications targeting theneurobiology underlying relapse offer additional avenues for treatmentGlutamate signaling iscritically involved ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Software and services to advance dose-response modeling in chemical risk assesment
SBC: KS & ASSOCIATES LLC Topic: NCATSPROJECT SUMMARY Chemical risk assessment has been widely applied in chemical industry as a necessary step to get new commercial chemicals registeredand in governmental agencies as a critical procedure to evaluate the toxicity of chemicals in order to properly regulate them to protect human health and the environmentThe Lautenberg Chemical Safety Act further strengthens the importance of chemical r ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A New Small-Molecule Kinase Inhibitor for Breast Cancer
SBC: NuPeak Therapeutics, Inc. Topic: 102NuPeak Therapeutics Incis a biotechnology start up companyC corporationdesigned to deliver a first inclass small molecule kinase inhibitorThe present Project is aimed at an inhibitor for treatment of breast cancerwhich remains a leading cause of morbidity and mortality in the U Sdespite current therapeutic approachesIn that contextwe identified a novel typeimmune response that activates mitogen ac ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health